<DOC>
	<DOC>NCT01739400</DOC>
	<brief_summary>Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.</brief_summary>
	<brief_title>Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Subjects with ES (including those with Down Syndrome) having completed the doubleblind AC055305 / MAESTRO study as scheduled, i.e., who remained in the doubleblind study up to Week 16 (whether or not they were still taking study drug at the end of this period). Subjects who prematurely discontinue doubleblind study drug during the AC055305 / MAESTRO study due to: an AE assessed as related to the use of study drug, or elevated liver tests (related or unrelated to study drug).</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Eisenmenger Syndrome</keyword>
	<keyword>exercise capacity</keyword>
</DOC>